Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis- stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study

Journal of Clinical Pharmacology

Volumn 47, Issue 12, 2007, Pages 1489-1497

  Kumagai, Yuji ^a   Fujita, Tomoe ^a   Ozaki, Machiko ^a   Sahashi, Kunihiko ^a   Ohkura, Masayuki ^b   Ohtsu, Tomoko ^b   Arai, Yoshihiro ^b   Sonehara, Yusuke ^b   Nichol, Janet L ^c  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b Amgen Limited   (Japan)

^c AMGEN INC   (United States)

Author keywords

AMG 531; Immune thrombocytopenic purpura; Platelet aggregation; Platelets; Thrombopoiesis; Thrombopoietin

Indexed keywords

AMG 531; PLACEBO; RECOMBINANT PROTEIN; THROMBOPOIESIS STIMULATING PEPTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEELING HOT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALAISE; MALE; MIGRAINE; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

ADULT; BLOOD PLATELETS; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEADACHE; HUMANS; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; PLATELET COUNT; RECEPTORS, FC;

EID: 36148972012     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007306563     Document Type: Article

References (25)

1. Bottiger LE, Westerholm B. Thrombocytopenia: I. Incidence and aetiology. Acta Med Scand. 1972 ; 191: 535-540.
2. George JN, El-Harake MA, Aster RH Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichman MA, Collier BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill ; 1995: 1315-1355.
3. Kelton JG, Gibbons S. Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. Semin Thromb Hemost. 1982 ; 8: 83-104.
4. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981 ; 304: 1135-1147.
5. Cohen YC, Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000 ; 160: 1630-1638.
6. McMillan R., Bussel JB, George JN, Lalla D., Nichol JL Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Unpublished manuscript; 2006.
7. Nakagawa M. Idiopathic Thrombocytopenic Purpura: A Practice Guideline for Diagnosis and Treatment of Intractable Diseases. Rev. ed Tokyo: Roppo Shuppansha ; 2001.
8. Omine M. [Epidemiology and long-term prognosis of ITP]. Nippon Rinsho. 2003 ; 61: 655-663.
9. Frederiksen H., Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999 ; 94: 909-913.
10. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 ; 88: 3-40.
11. McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004 ; 104: 956-960.
12. Emilia G., Longo G., Luppi M., et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood. 2001 ; 97: 812-814.
13. Kohda K., Kuga T., Kogawa K., et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol. 2002 ; 118: 584-588.
14. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a novel thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 ; 355: 1672-1681.
15. Broudy VC, Lin NL AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004 ; 25: 52-60.
16. Marsh JC, Gibson FM, Prue RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol. 1996 ; 95: 605-610.
17. Newland A., Caulier MT, Kappers-Klunne M., et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006 ; 135: 547-553.
18. Wang B., Nichol JL, Sullivan JT Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004 ; 76: 628-638.
19. Mason S., La S., Mytych D., Swanson SJ, Ferbas J. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin. 2003 ; 19: 651-659.
20. Mire-Sluis AR, Barrett YC, Devanarayan V., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004 ; 289: 1-16.
21. Gupta S., Indelicato SR, Jethwa V., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007 ; 321: 1-18.
22. Manoharan A., Brighton T., Gemmell R., Lopez K., Moran S., Kyle P. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. Int J Hematol. 2002 ; 76: 272-278.
23. O'Malley CJ, Rasko JE, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 1996 ; 88: 3288-3298.
24. Albert LJ, Inman RD Molecular mimicry and autoimmunity. N Engl J Med. 1999 ; 341: 2068-2074.
25. Oldstone MB Molecular mimicry and immune-mediated diseases. Faseb J. 1998 ; 12: 1255-1265.